Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Naturland Holding ZrtBUD:NATURLAND 61 3-Year EBITDA Growth Rate is 9.40% as of Jun. 2025, which is 83% below its 10-year median of 54.05. GuruFocus rates BUD:NATURLAND with a GF Score™ of 61/100 and a GF Value™ of Ft2,894.15 (Fairly Valued). The stock has 5 warning signs investors should review. Among 813 Drug Manufacturers companies, Naturland Holding Zrt ranks better than 51.41% on this metric.
During the past 12 months, Naturland Holding Zrt's average EBITDA Per Share Growth Rate was 12.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 9.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Naturland Holding Zrt was 98.70% per year. The lowest was 9.40% per year. And the median was 54.05% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Naturland Holding Zrt 3-Year EBITDA Growth Rate Related Terms
BUD:NATURLAND vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Naturland Holding Zrt's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturland Holding Zrt 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Naturland Holding Zrt's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Naturland Holding Zrt's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 9.40% mean?
Naturland Holding Zrt (BUD:NATURLAND) has a 3-Year EBITDA Growth Rate of 9.40% as of Jun. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Naturland Holding Zrt and its competitors. This is 83% below median its historical median of 54.05. Over the past decade, Naturland Holding Zrt's 3-Year EBITDA Growth Rate has ranged from 9.40 to 98.70. According to the industry distribution chart, Naturland Holding Zrt ranks #395 out of 813 companies in the Drug Manufacturers industry, placing it in the top 48.6%.
Is Naturland Holding Zrt's 3-Year EBITDA Growth Rate too high?
Naturland Holding Zrt's current 3-Year EBITDA Growth Rate of 9.40% is 83% below median its 10-year median of 54.05. Over the past 10 years, this metric has ranged from a low of 9.40 to a high of 98.70. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Naturland Holding Zrt's value of 9.40% is 5.6% above this industry median. Based on the distribution chart, Naturland Holding Zrt ranks #395 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Naturland Holding Zrt has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Naturland Holding Zrt's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Naturland Holding Zrt ranks #395 out of 813 companies for 3-Year EBITDA Growth Rate. This puts Naturland Holding Zrt in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Naturland Holding Zrt's value of 9.40% is 5.6% above this benchmark. Historically, Naturland Holding Zrt's own 3-Year EBITDA Growth Rate has ranged from 9.40 to 98.70 over the past decade. While the company's 10-year median is 54.05 vs. the industry median of 8.90, Naturland Holding Zrt has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Naturland Holding Zrt's current 3-Year EBITDA Growth Rate of 9.40% is 5.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Naturland Holding Zrt and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Naturland Holding Zrt's current 3-Year EBITDA Growth Rate is 9.40%, which is 83% below median its own 10-year median of 54.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturland Holding Zrt stock overvalued right now?
Based on GuruFocus' analysis, Naturland Holding Zrt (BUD:NATURLAND) is currently considered Fairly Valued. The stock's GF Value™ is Ft2,894.15, compared to a current price of Ft2,740.00 — trading 5.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 9.40%, which is 83% below median its 10-year median of 54.05 and 5.6% above the Drug Manufacturers industry median of 8.90. Naturland Holding Zrt's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Naturland Holding Zrt (BUD:NATURLAND), the current 3-Year EBITDA Growth Rate is 9.40% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturland Holding Zrt (BUD:NATURLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Naturland Holding Zrt stock appears to be undervalued.
The current stock price of Ft2,740.00 is trading 5.3% below its estimated GF Value™ of Ft2,894.15.
GuruFocus considers Naturland Holding Zrt to be Fairly Valued.
Key valuation signals for BUD:NATURLAND:
3-Year EBITDA Growth Rate: 9.40% (83% below median its 10-year median of 54.05)
GF Value™: Ft2,894.15 vs. price of Ft2,740.00 (5.3% below fair value)
Industry Position: 5.6% above the Drug Manufacturers median (#395 of 813)
No single metric tells the full story. See the BUD:NATURLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturland Holding Zrt thro9ugh its subsidiaries engage in the production of pharmaceutical products. It engages in the development, production, and wholesale of dietary supplements and cosmetics, herbal medicine, teas, and essential oils. The firm offers tablets, suppositories, ointments, and ophthalmic base solutions.
61GF Score
Get the complete analysis for BUD:NATURLAND
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NATURLAND has been successfully added to your 
